INTRODUCTION
============

Asthma is a heterogeneous and genetically complex respiratory disease.[@B1] Approaches for gene discovery in asthma were initially candidate gene association studies, followed by family-based genome-wide linkage analyses and, most recently, genome-wide association studies (GWASs).[@B2][@B3] For the last decade, GWASs of asthma have dominated, providing bias-free discovery of novel risk loci.[@B4]

The first GWAS of asthma was reported in 2007.[@B5] As of July 10, 2018 there were 72 papers written in English on asthma or asthma-related traits reported in the GWAS catalog (<https://www.ebi.ac.uk/gwas/>). Among these 72 papers, 24 are GWASs of asthmatic subjects and controls, including 7 meta-analyses of asthma GWASs ([Table 1](#T1){ref-type="table"}); 5 are GWASs of asthma sub-phenotypes such as severe asthma or asthma exacerbations; 13 are GWASs of asthma-related traits such as bronchodilator response (BDR), airway hyperresponsiveness (AHR) and total serum immunoglobulin E (IgE) levels; 15 are GWASs of asthma combined with other diseases, such as allergic rhinitis, or factors such as smoking interaction or age of onset; 2 are GWASs of occupational asthma; 2 are GWASs of aspirin-exacerbated respiratory disease (AERD); and 11 are GWASs of asthma pharmacologic responses.

###### Characteristics of GWASs of asthma

![](aair-11-170-i001)

  Year   Author               Discovery stage     Replication stage                        Combined analysis   Reference                                                                                                
  ------ -------------------- ------------------- ---------------------------------------- ------------------- ----------- ------------------------------------- ------------------------------ ----- ------- --------- --------
  2007   Moffatt MF           European            994 cases and 1,243 controls             Yes                 1           European                              5,621 subjects                 Yes   1       NA        [@B5]
  2009   Hancock DB           Latino              492 trios                                Yes                 0           Hispanic                              177 trios                      Yes   NA      NA        [@B76]
  2009   Himes BE             European            359 cases and 846 controls               Yes                 0           Multi-ethnic                          24,155 subjects                Yes   NA      NA        [@B39]
  2010   Sleiman PM           European            793 cases and 1,988 controls             Yes                 2           European, African American            6,175 subjects                 Yes   1^†^    2^‡^      [@B77]
  2010   Himes BE             European            359 cases, 846 controls, and 403 trios   Yes                 0           Multi-ethnic                          8,550 subjects and 583 trios   No    NA      NA        [@B78]
  2010   Mathias RA           African American    498 cases and 500 controls               No                  0           African Caribbean, African American   6,134 subjects                 No    NA      0         [@B79]
  2010   DeWan AT             Multi-ethnic        66 cases and 42 controls                 Yes                 0           European, Hispanic                    12,337 subjects                No    NA      0         [@B80]
  2011   Ferreira MA          European            986 cases and 1,846 controls             No                  0           European                              604 subjects                   No    NA      NA        [@B81]
  2011   Ferreira MA          European            12,475 cases and 19,967 controls         No                  8^§^        European                              25,358 subjects                No    NA      2         [@B82]
  2011   Noguchi E            Asian               938 cases and 2,376 controls             Yes                 2           Asian                                 3,106 subjects                 Yes   2       2^‡^      [@B83]
  2011   Hirota T             Asian               1,532 cases and 3,304 controls           No                  1           Asian                                 30,247 subjects                No    0       5^∥^      [@B84]
  2012   Lasky-Su J           European            1,238 cases and 2,617 controls           No                  2^¶^        European                              11,199 subjects                No    NA      1^\*\*^   [@B85]
  2012   Li X                 European            813 cases and 1,564 controls             No                  0           Multi-ethnic                          41,400 subjects                No    NA      NA        [@B86]
  2014   Galanter JM          Latino              1,893 cases and 1,881 controls           Yes                 1           Multi-ethnic                          12,560 subjects                No    NA      NA        [@B87]
  2016   White MJ             African American    812 cases and 415 controls               Yes                 1           NA                                    NA                             NA    NA      NA        [@B88]
  2016   Nieuwenhuis MA       European            920 cases and 980 controls               No                  0           Multi-ethnic                          11,656 subjects                No    NA      1         [@B89]
  2016   Barreto-Luis A       European            380 cases and 552 controls               No                  0           European                              2,352 subjects                 No    NA      0         [@B90]
  2010   Moffatt MF^††^       European            10,365 cases and 16,110 controls         No                  7^‡‡^       NA                                    NA                             NA    NA      NA        [@B16]
  2011   Torgerson DG^§§^     Multi-ethnic        5,416 cases and 7,144 controls           No                  4^∥∥^       Multi-ethnic                          12,649 subjects                No    3^¶¶^   3^¶¶^     [@B19]
  2012   Ramasamy A^\*\*\*^   European            1,716 cases and 16,888 controls          No                  0           European                              15,286 subjects                No    NA      2         [@B91]
  2016   Pickrell JK          European            28,399 cases and 128,843 controls        No                  27          NA                                    NA                             NA    NA      NA        [@B21]
  2017   Yan Q                Latino              2,144 cases and 2,893 controls           No                  1           NA                                    NA                             NA    NA      NA        [@B92]
  2017   Almoguera B          European, African   5,309 cases and 16,335 controls          No                  2           NA                                    NA                             NA    NA      NA        [@B34]
  2018   Demenais F^†††^      Multi-ethnic        23,948 cases and 118,538 controls        No                  18          NA                                    NA                             NA    NA      NA        [@B14]

References are sorted by year. "Mixed" in childhood onset asthma denotes the unknown proportion of childhood onset asthma.

NA, not applicable; GWAS, genome-wide association study; GABRIEL, Multidisciplinary Study to Identify the Genetic and Environmental Causes of Asthma in the European Community; SNP, single nucleotide polymorphism.

^\*^Specifications of the discovery stage genome-wide significant *P* value definitions are in [Supplementary Table S1](#S1){ref-type="supplementary-material"}; ^†^Replication data were shown in only the non-17q12-21 region; ^‡^Both loci are also genome-wide significant in the discovery GWAS; ^§^One loci from the results of the Australian GWAS only and seven loci from the results of the Australian GWAS and GABRIEL; ^∥^Genome-wide significant *P* value of the replication stage was less than 5.0 × 10^−8^; ^¶^From the adult asthma GWAS results only; ^\*\*^From the adult asthma combined analysis; ^††^Meta-Analysis includes GWAS from reference [@B5]; ^‡‡^Loci including SNPs showing genome-wide significant association with asthma in at least one group using fixed models; ^§§^Meta-Analysis includes GWAS from references [@B19][@B39][@B76][@B77][@B79]; ^∥∥^Loci including SNPs showing genome-wide significant association with asthma in at least one ethnic group; ^¶¶^Replication and combined analysis were done in selected 15 loci; ^\*\*\*^Meta-Analysis includes GWAS from reference s19,39,83,85; ^†††^Meta-Analysis includes GWAS from references [@B5][@B19][@B79][@B82][@B83][@B85][@B90].

In this review, we summarize the results of the 42 GWASs of asthma, asthma sub-phenotypes (*e.g.*, severe asthma, asthma exacerbation) and asthma-related traits (*e.g.*, BDR, AHR, total serum IgE) that are registered in the GWAS catalog. We discuss the challenges posed by GWASs of complex diseases and strategies to overcome these challenges. Other aspects of asthma genetics, such as gene-environment interactions,[@B6][@B7][@B8] occupational asthma,[@B9] AERD[@B10][@B11] or pharmacogenetics[@B12][@B13] are reviewed elsewhere.

GWAS OF ASTHMA
==============

[Table 1](#T1){ref-type="table"} summarizes the study populations, sample sizes, and results of the 17 GWASs and 7 meta-analyses of asthma. Additional information on characteristics of the study populations is included in [Supplementary Table S1](#S1){ref-type="supplementary-material"}.

Eight GWASs and 6 meta-analyses reported one or more association with genome-wide significance in the discovery population. Two additional GWASs reported genome-wide significance in a combined --- discovery and replication --- sample. These 16 studies together described 35 loci that were significant in at least 1 study ([Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}, [Supplementary Tables S2](#S2){ref-type="supplementary-material"} and [S3](#S3){ref-type="supplementary-material"}). Sixteen of the 35 loci showed nominal significance when replicated in other GWASs, and 14 of those 16 loci showed genome-wide significant associations in at least 2 papers. Taken together, 5 GWASs and 5 meta-analyses of asthma identified genome-wide significant single nucleotide polymorphisms (SNPs) (*P* \< 5 × 10^−8^) at the 17q12-21 (*ORMDL3*, *GSDMB*), making this the most widely replicated asthma loci. The 6p21 (HLA region), 2q12 (*IL1RL1*/*IL18R1*), 5q22 (*TSLP*) and 9p24 (*IL33*) loci showed the next 4 most genome-wide significant associations ([Figure](#F1){ref-type="fig"}, [Table 3](#T3){ref-type="table"}).

###### Asthma susceptibility loci meeting criteria for genome-wide significance in either discovery or combined stage in each GWAS

![](aair-11-170-i002)

  Year            Author                                                                        Region        Reported genes                         Lead SNP     Location (Bp)   RAF in controls   *P* value    OR          95% CI       Stage       Replication *P* value   Reference
  --------------- ----------------------------------------------------------------------------- ------------- -------------------------------------- ------------ --------------- ----------------- ------------ ----------- ------------ ----------- ----------------------- -----------
  2007            Moffatt MF^\*^                                                                17q21         *ORMDL3*                               rs7216389    39913696        NA                1.00.E-10    NA          NA           Discovery   7.94.E-04               [@B5]
  2010            Sleiman PM                                                                    1q31          *DENND1B*                              rs2786098    197356778       0.78              8.55.E-09    1.59        1.28--1.61   Discovery   6.47.E-04               [@B77]
  17q21           *ORMDL3*/*GSDMB*                                                              rs4795400     39910767                               NA           2.08.E-08       1.28              NA           Discovery   NA                                               
  2011            Ferreira MA^†,‡^                                                              1q21          *IL6R*                                 rs4129267    154453788       0.40              2.30.E-08    1.09        1.06--1.12   Combined    3.30.E-03               [@B82]
  2q12            *IL1RL1*                                                                      rs3771166     102369762                              0.61         7.90.E-15       1.16              1.11--0.20   Discovery   NA                                               
  5q22            *WDR36*                                                                       rs1043828     111128310                              0.35         1.10.E-08       1.11              1.07--1.15   Discovery   NA                                               
  5q31            *RAD50*                                                                       rs6871536     132634182                              0.19         2.40.E-09       1.14              1.09--1.19   Discovery   NA                                               
  9p24            *IL33*                                                                        rs1342326     6190076                                0.16         3.50.E-14       1.20              1.14--1.26   Discovery   NA                                               
  11q13           *C11orf30*/*LRRC32*                                                           rs7130588     76559639                               0.36         1.80.E-08       1.09              1.06--1.13   Combined    3.28.E-02                                        
  15q22           *RORA*                                                                        rs11071559    60777789                               0.86         3.80.E-09       1.18              1.11--1.23   Discovery   NA                                               
  15q22           *SMAD3*                                                                       rs744910      67154447                               0.49         2.70.E-09       1.11              1.07--1.15   Discovery   NA                                               
  17q21           *ORMDL3*                                                                      rs8079416     39936460                               0.44         2.40.E-22       1.19              1.15--1.23   Discovery   NA                                               
  22q12           *IL2RB*                                                                       rs2284033     37137994                               0.57         5.00.E-10       1.12              1.09--1.16   Discovery   NA                                               
  2011            Noguchi E^§^                                                                  6p21          *HLA-DPB1*                             rs987870     33075103        0.14              7.50.E-09    1.51        1.31--1.74   Discovery   1.20.E-02               [@B83]
  8q24            *SLC30A8*                                                                     rs3019885     117013406                              0.31         1.30.E-14       1.55              1.39--1.73   Discovery   8.70.E-03                                        
  2011            Hirota T                                                                      4q31          *USP38*                                rs7686660    143082006       0.27              1.87.E-12    1.16        1.11--1.21   Combined    3.33.E-09               [@B84]
  5q22            *TSLP*                                                                        rs1837253     111066174                              0.35         1.24.E-16       1.17              1.13--1.22   Combined    1.02.E-12                                        
  6p21            *PBX2*/*NOTCH4*/*C6orf10*/*BTNL2*/*HLA-DRA*/*HLA-DQB1*/*HLA-DQA2*/*HLA-DOA*   rs404860      32216568                               0.50         4.07.E-23       1.21              1.16--1.25   Combined    6.42.E-18                                        
  10p14           \-                                                                            rs10508372    8930055                                0.43         1.79.E-15       1.16              1.12--1.21   Combined    1.31.E-11                                        
  12q13           *CDK2*/*IKZF4*                                                                rs1701704     56018703                               0.18         2.33.E-13       1.19              1.14--1.25   Combined    7.22.E-09                                        
  2012            Lasky-Su J                                                                    5p15          *FLJ25076*                             rs272474     6462225         NA                3.78.E-08    NA          NA           Discovery   NA                      [@B85]
  6p21            *HLA-DQA1*                                                                    rs9272346     32636595                               NA           2.20.E-08       NA                NA           Combined    6.70.E-03                                        
  14q13           *AKAP6*                                                                       rs17441370    32775658                               NA           1.37.E-11       NA                NA           Discovery   NA                                               
  2014            Galanter JM                                                                   17q12         *IKZF3*                                rs907092     39766006        0.70              5.70.E-13    1.49        1.33--1.64   Discovery   NA                      [@B87]
  2016            White MJ                                                                      10p12         *PTCHD3*                               rs660498     27452030        0.46              2.20.E-07    1.62        1.35--1.95   Discovery   NA                      [@B88]
  2016            Nieuwenhuis MA                                                                17q21         *IKZF3*/*ZPBP2*/*GSDMB*/*ORMDL3*       rs2290400    39909987        NA                2.55.E-20    1.31        NA           Combined    6.78.E-17               [@B89]
  Meta-analysis                                                                                                                                                                                                                                                               
  2010            Moffatt MF^∥^                                                                 2q12          *IL1RL2*/*IL1RL1*/*IL18R1*/*IL18RAP*   rs3771166    102369762       0.62              3.40.E-09    1.15        1.10--1.20   Discovery   NA                      [@B16]
  6p21            *CCHCR1*/*HLA-DQB1*                                                           rs9273349     32658092                               0.58         7.00.E-14       1.18              1.13--1.24   Discovery   NA                                               
  9p24            *RANBP6*/*IL33*                                                               rs1342326     6190076                                0.16         9.20.E-10       1.20              1.13--1.28   Discovery   NA                                               
  15q22           *SMAD3*                                                                       rs744910      67154447                               0.49         3.90.E-09       1.12              1.09--1.16   Discovery   NA                                               
  17q12           *STARD3*/*TCAP*/*PGAP3*/*ERBB2*/*IKZF3*/*ZPBP2*                               rs9303277     39820216                               0.51         1.62.E-16       0.82              0.79--0.86   Discovery   NA                                               
  17q21           *GSDMB*/*ORMDL3*                                                              rs2305480     39905943                               0.55         9.60.E-08       1.18              1.11--1.23   Discovery   NA                                               
  17q21           *GSDMA*/*PSMD3*/*MED24*                                                       rs3894194     39965740                               0.45         4.60.E-09       1.17              1.11--1.23   Discovery   NA                                               
  22q12           *IL2RB*                                                                       rs2284033     37137994                               0.56         1.20.E-08       1.12              1.08--1.16   Discovery   NA                                               
  2011            Torgerson DG                                                                  2q12          *IL1RL1*                               rs3771180    102337157       0.86              1.50.E-15    1.20        1.11--1.29   Combined    5.30.E-07               [@B19]
  3q27            *RTP2*                                                                        rs2017908     187699930                              0.13         4.42.E-09^¶^    1.63              1.43--1.82   Discovery   8.80.E-01                                        
  5q22            *TSLP*                                                                        rs1837253     111066174                              0.74         1.00.E-14       1.19              1.12--1.27   Combined    1.60.E-06                                        
  9p24            *IL33*                                                                        rs2381416     6193455                                0.70         1.70.E-12       1.18              1.08--1.28   Combined    1.30.E-06                                        
  17q21           *GSDMB*                                                                       rs11078927    39908152                               0.55         2.20.E-16       1.27              1.20--1.34   Combined    1.50.E-08                                        
  2012            Ramasamy A                                                                    2q12          *IL1RL1*/*IL18R1*                      rs13408661   102338622       0.84              1.00.E-09    1.23        1.15--1.31   Combined    3.20.E-05               [@B91]
  6p21            *BTNL2*/*HLA-DRA*                                                             rs9268516     32411712                               0.24         1.00.E-08       1.15              1.10--1.21   Combined    1.00.E-03                                        
  2016            Pickrell JK                                                                   1q23          *ADAMTS4*                              rs4233366    161189357       NA                4.80.E-15    1.09        1.07--1.11   Discovery   NA                      [@B21]
  1q24            *CD247*                                                                       rs1723018     167464183                              NA           1.40.E-08       0.95              0.93--0.96   Discovery   NA                                               
  1q25            *TNFSF4*                                                                      rs6691738     173182897                              NA           2.90.E-08       0.94              0.92--0.96   Discovery   NA                                               
  1q32            *ADORA1*                                                                      rs6683383     203131376                              NA           1.10.E-08       1.06              1.04--1.08   Discovery   NA                                               
  1p36            *PEX14*                                                                       rs662064      10497194                               NA           3.20.E-08       0.94              0.92--0.96   Discovery   NA                                               
  2q12            *IL1RL1*                                                                      rs202011557   102297183                              NA           5.10.E-31       0.84              0.82--0.87   Discovery   NA                                               
  2p25            \-                                                                            rs13412757    8317950                                NA           1.30.E-08       1.06              1.04--1.08   Discovery   NA                                               
  2q37            *D2HGDH*                                                                      rs34290285    241759225                              NA           1.80.E-15       1.11              1.08--1.14   Discovery   NA                                               
  3q28            *LPP*                                                                         rs73196739    188684683                              NA           6.50.E-09       0.92              0.90--0.95   Discovery   NA                                               
  4p14            *TLR1*                                                                        rs5743618     38797027                               NA           3.90.E-11       1.08              1.06--1.11   Discovery   NA                                               
  5q22            *TSLP*                                                                        rs1837253     111066174                              NA           3.30.E-31       0.88              0.86--0.90   Discovery   NA                                               
  5q31            *RAD50*                                                                       rs2244012     132565533                              NA           2.10.E-16       1.10              1.08--1.13   Discovery   NA                                               
  5q31            *NDFIP1*                                                                      rs200634877   142150197                              NA           2.50.E-08       0.94              0.92--0.96   Discovery   NA                                               
  6q15            *BACH2*                                                                       rs58521088    90275479                               NA           7.10.E-11       0.93              0.92--0.95   Discovery   NA                                               
  6p21            *HLA-DQA1*                                                                    rs3104367     32635710                               NA           1.00.E-40       0.87              0.86--0.89   Discovery   NA                                               
  6p21            *HLA-C*/*MICA*                                                                rs2428494     31354420                               NA           1.40.E-16       0.92              0.90--0.94   Discovery   NA                                               
  7q22            *CDHR3*                                                                       rs6959584     106035809                              NA           2.00.E-08       1.09              1.06--1.12   Discovery   NA                                               
  8q21            \-                                                                            rs10957978    80372904                               NA           1.10.E-11       0.93              0.92--0.95   Discovery   NA                                               
  9p24            *IL33*                                                                        rs144829310   3208030                                NA           1.30.E-31       1.17              1.14--1.20   Discovery   NA                                               
  10p14           \-                                                                            rs12413578    9007290                                NA           8.10.E-12       0.89              0.86--0.92   Discovery   NA                                               
  11q13           *C11orf30*/*LRRC32*                                                           rs7936323     76582714                               NA           1.40.E-16       0.92              0.91--0.94   Discovery   NA                                               
  12q13           *STAT6*                                                                       rs3001426     57115272                               NA           1.40.E-10       0.94              0.92--0.96   Discovery   NA                                               
  14q24           *RAD51B*                                                                      rs3784099     68283210                               NA           1.60.E-08       0.94              0.92--0.96   Discovery   NA                                               
  15q22           \-                                                                            rs10519068    60776505                               NA           3.80.E-11       1.10              1.07--1.13   Discovery   NA                                               
  15q22           *SMAD3*                                                                       rs56375023    67156025                               NA           2.40.E-21       0.90              0.88--0.92   Discovery   NA                                               
  16p13           *CLEC16A*                                                                     rs7203459     11136846                               NA           3.50.E-15       1.09              1.07--1.12   Discovery   NA                                               
  17q12           *ZPBP2*                                                                       rs11655198    39869916                               NA           1.00.E-63       0.85              0.83--0.86   Discovery   NA                                               
  2017            Yan Q                                                                         17q12         *IKZF3*                                rs907092     39766006        0.68              1.16.E-12    1.41        NA           Discovery   NA                      [@B92]
  2017            Almoguera B                                                                   6p21          *GRM4*                                 rs1776883    34188667        0.47              5.29.E-09    1.25        1.19--1.31   Discovery   NA                      [@B34]
  9p21            *EQTN*                                                                        rs72721168    27308290                               0.96         7.02.E-10       1.83              1.28--2.37   Discovery   NA                                               
  2018            Demenais F^\*\*^                                                              2q12          *IL1RL1*                               rs1420101    102341256       0.37              3.9.E-21     1.12        1.09--1.15   Discovery   NA                      [@B14]
  5q22            *SLC25A46*                                                                    rs10455025    111069301                              0.34         9.4.E-26        1.15              1.12--1.18   Discovery   NA                                               
  5q31            *IL13*                                                                        rs20541       111069301                              0.79         5.0.E-16        0.89              0.87--0.92   Discovery   NA                                               
  5q31            *NDFIP1*                                                                      rs7705042     142112854                              0.63         7.9.E-9         1.09              1.06--1.12   Discovery   NA                                               
  6p21            *HLA-DRB1*                                                                    rs9272346     32636595                               0.56         5.7.E-24        1.16              1.12--1.19   Discovery   NA                                               
  6p21            *MICB*                                                                        rs2855812     31504943                               0.23         8.9.E-12        1.1               1.07--1.13   Discovery   NA                                               
  6p22            *GPX5*                                                                        rs1233578     28744470                               0.13         5.9.E-7         1.09              1.05--1.12   Discovery   NA                                               
  6q15            *BACH2*                                                                       rs2325291     90276967                               0.33         2.2.E-12        0.91              0.89--0.94   Discovery   NA                                               
  8q21            *TPD52*                                                                       rs12543811    80366650                               0.66         1.1.E-10        0.92              0.90--0.95   Discovery   NA                                               
  9p24            *RANBP6*                                                                      rs992969      6209697                                0.75         7.2.E-20        0.86              0.83--0.88   Discovery   NA                                               
  10p14           *GATA3*                                                                       rs2589561     9004682                                0.82         3.5.E-9         0.91              0.88--0.94   Discovery   NA                                               
  11q13           *EMSY*                                                                        rs7927894     76590272                               0.37         2.2.E-14        1.1               1.08--1.13   Discovery   NA                                               
  12q13           *STAT6*                                                                       rs167769      57109992                               0.4          3.9.E-9         1.08              1.05--1.11   Discovery   NA                                               
  15q22           *RORA*                                                                        rs11071558    60777222                               0.14         1.3.E-9         0.89              0.86--0.92   Discovery   NA                                               
  15q22           *SMAD3*                                                                       rs2033784     67157322                               0.3          7.4.E-15        1.1               1.08--1.13   Discovery   NA                                               
  16p13           *CLEC16A*                                                                     rs17806299    11106123                               0.2          2.7.E-10        0.91              0.88--0.94   Discovery   NA                                               
  17q12           *ERBB2*                                                                       rs2952156     39720582                               0.7          2.2.E-30        0.87              0.84--0.89   Discovery   NA                                               
  17q21           *ZNF652*                                                                      rs17637472    49384071                               0.39         6.6.E-9         1.08              1.05--1.11   Discovery   NA                                               

The most significant SNPs at each locus are shown and ordered by genomic location in each reference. Base pair positions (bp) correspond to *GRCh38/hg38* genome assembly.

SNP, single nucleotide polymorphism; RAF, risk allele frequency; OR, odds ratio; CI, confidence interval; FDR, false discovery rate; GWAS, genome-wide association study; GABRIEL, Multidisciplinary Study to Identify the Genetic and Environmental Causes of Asthma in the European Community.

^\*^With the exception of the 17q12-21 locus, none of the markers below 5% FDR, after controlling for stratification, were within 1 Mb of each other; ^†^Discovery GWAS was the meta-analysis of results from the Australian GWAS and GABRIEL; ^‡^RAF was from the Australian GWAS only; ^§^RAF was from the discovery GWAS only; ^∥^*P* value of random effects; ^¶^*P* vaule from the Latino GWAS only; ^\*\*^RAF was allele effect frequency from the European GWAS only.

###### Locus-level replications in subsequent GWAS

![](aair-11-170-i003)

  Reported genes                                                                                      Region     The initial report   Genome-wide significant replication, reference   Nominal replication, reference                                                            
  --------------------------------------------------------------------------------------------------- ---------- -------------------- ------------------------------------------------ -------------------------------- -------------------------------------------------------- --------------------------------------------------------
  *STARD3*/*TCAP*/*PGAP3*/*ERBB2*/*IKZF3*/*ZPBP2*/*GSDMB*/*ORMDL3*/*GSDMA*/*ZNF652*/*PSMD3*/*MED24*   17q12-21   rs7216389            1.00.E-10                                        [@B5]                            [@B14][@B16][@B19][@B21][@B77][@B82][@B87][@B89][@B92]   [@B34][@B39][@B78][@B81][@B83][@B85][@B86][@B90][@B91]
  *CCHCR1*/*PBX2*/*NOTCH4*/*C6orf10*/*BTNL2*/*GRM4*/*HLA region*/*MICB*/*MICA*                        6p21       rs9273349            7.00.E-14                                        [@B16]                           [@B14][@B21][@B34][@B83][@B84][@B85][@B91]               [@B19][@B82][@B86][@B87][@B88][@B89][@B92]
  *IL1RL2*/*IL1RL1*/*IL18R1*/*IL18RAP*                                                                2q12       rs3771166            3.40.E-09                                        [@B16]                           [@B14][@B19][@B21][@B82][@B91]                           [@B34][@B81][@B84][@B85][@B86][@B87][@B90][@B92]
  *TSLP*/*WDR36*/*SLC25A46*                                                                           5q22       rs1043828            1.10.E-08                                        [@B82]                           [@B14][@B19][@B21][@B84]                                 [@B34][@B85][@B86][@B87][@B90][@B92]
  *IL33*/*RANBP6*                                                                                     9p24       rs1342326            9.20.E-10                                        [@B16]                           [@B14][@B19][@B21][@B82]                                 [@B19][@B34][@B84][@B85][@B86][@B87][@B89][@B90][@B91]
  *SMAD3*/*RORA*                                                                                      15q22      rs744910             3.90.E-09                                        [@B16]                           [@B14][@B21][@B82]                                       [@B19][@B83][@B84][@B91][@B92]
  *RAD50*/*IL13*/*NDFIP1*                                                                             5q31       rs6871536            2.40.E-09                                        [@B82]                           [@B14][@B21]                                             [@B19][@B34][@B83][@B84][@B90]
  *C11orf30*/*LRRC32*/*EMSY*                                                                          11q13      rs7130588            1.80.E-08                                        [@B82]                           [@B14][@B21]                                             [@B90]
  *IKZF4*/*CDK2*/*STAT6*                                                                              12q13      rs1701704            2.33.E-13                                        [@B84]                           [@B14][@B21]                                             [@B90]
  *IL2RB*                                                                                             22q12      rs2284033            1.20.E-08                                        [@B16]                           [@B82]                                                   [@B83][@B84][@B87][@B89][@B92]
  *BACH2*                                                                                             6q15       rs58521088           7.10.E-11                                        [@B21]                           [@B14]                                                   NA
  *TPD52*                                                                                             8q21       rs12543811           1.10.E-10                                        [@B21]                           [@B14]                                                   NA
  *GATA3*                                                                                             10p14      rs2589561            3.50.E-09                                        [@B84]                           [@B14]                                                   NA
  *CLEC16A*                                                                                           16p13      rs17806299           3.50.E-15                                        [@B21]                           [@B14]                                                   NA
  *DENND1B*                                                                                           1q31       rs2786098            8.55.E-09                                        [@B77]                           NA                                                       [@B84]
  *SLC30A8*                                                                                           8q24       rs3019885            5.00.E-13                                        [@B83]                           NA                                                       [@B88]
  *PEX14*                                                                                             1p36       rs662064             3.20.E-08                                        [@B21]                           NA                                                       NA
  *IL6R*                                                                                              1q21       rs4129267            2.30.E-08                                        [@B82]                           NA                                                       NA
  *ADAMTS4*                                                                                           1q23       rs4233366            4.80.E-15                                        [@B21]                           NA                                                       NA
  *CD247*                                                                                             1q24       rs1723018            1.40.E-08                                        [@B21]                           NA                                                       NA
  *TNFSF4*                                                                                            1q25       rs6691738            2.90.E-08                                        [@B21]                           NA                                                       NA
  *ADORA1*                                                                                            1q32       rs6683383            1.10.E-08                                        [@B21]                           NA                                                       NA
  \-                                                                                                  2p25       rs13412757           1.30.E-08                                        [@B21]                           NA                                                       NA
  *D2HGDH*                                                                                            2q37       rs34290285           1.80.E-15                                        [@B21]                           NA                                                       NA
  *RTP2*                                                                                              3q27       rs2017908            4.42.E-09                                        [@B19]                           NA                                                       NA
  *LPP*                                                                                               3q28       rs73196739           6.50.E-09                                        [@B21]                           NA                                                       NA
  *TLR1*                                                                                              4p14       rs5743618            3.90.E-11                                        [@B21]                           NA                                                       NA
  *USP38*                                                                                             4q31       rs7686660            1.87.E-12                                        [@B84]                           NA                                                       NA
  *FLJ25076*                                                                                          5p15       rs272474             3.78.E-08                                        [@B85]                           NA                                                       NA
  *GPX5*                                                                                              6p22       rs1233578            5.90.E-07                                        [@B14]                           NA                                                       NA
  *CDHR3*                                                                                             7q22       rs6959584            2.00.E-08                                        [@B21]                           NA                                                       NA
  *EQTN*                                                                                              9p21       rs72721168           7.02.E-10                                        [@B34]                           NA                                                       NA
  *PTCHD3*                                                                                            10p12      rs660498             2.20.E-07                                        [@B88]                           NA                                                       NA
  *AKAP6*                                                                                             14q13      rs17441370           1.37.E-11                                        [@B85]                           NA                                                       NA
  *RAD51B*                                                                                            14q24      rs3784099            1.60.E-08                                        [@B21]                           NA                                                       NA

The table is sorted by the most number of repeatedly replicated loci. There were no replication data of previously reported GWAS in references [@B5][@B76][@B79][@B80]. Nominal replication signifies the SNPs at each locus with replication *P* value less than 0.05 when there were replication data of previously reported GWASs.

GWAS, genome-wide association study; SNP, single nucleotide polymorphism.
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A recent meta-analysis of 23,948 asthma cases and 118,538 controls from the Trans-National Asthma Genetic Consortium (TAGC) revealed 18 loci that met the criteria of genome-wide significance,[@B14] including nine previously known asthma loci, 2 loci previously reported for asthma plus hay fever, 2 previously associated with asthma in ancestry-specific populations and 5 new asthma susceptible loci. The latter included loci at 5q31.3, 6p22.1, 6q15, 12q13.3 and 17q21.33. Nearly all of the lead SNPs at the new loci were located in noncoding regions, and some were expression quantitative trait loci (eQTL) for genes such as *NDFIP1* (chromosome 5q31.3), *ZSCAN12* and *ZSCAN31* (6p22.1), *BACH2* (6q15), *STAT6* (12q13.3) and *GNGT2* (17q21.33). An enrichment in enhancer marks, especially in immune cells, was found at the associated loci, suggesting that the associated SNPs, or SNPs in linkage disequilibrium (LD) with the associated SNPs, play a role in the regulation of the immune processes.

Since the first GWAS of asthma that identified variants at the 17q21 locus and the correlation of those variants with expression of *ORMDL3*,[@B5] this region has been the most frequently studied and replicated locus. This region harbors a dense haploblock of SNPs that overlap at least 4 genes: *IKZF3*, *ZPBP2*, *GSDMB and ORMDL3*. The locus has since been extended to include regions flanking this core region, implicating *PGAP3* and *ERBB2* at the proximal end and *GSDMA* at the distal end as potentially representing independent asthma loci.[@B15] Nineteen asthma GWASs overall reported associations with SNPs at the extended 17q12-21 locus ([Table 3](#T3){ref-type="table"}). Moffatt *et al*.[@B16] carried out a subgroup analysis of childhood-onset asthma and reported the association of this region specific to childhood-onset asthma, but had few later-onset asthma individuals to separately analyze that subgroup in their consortium-based meta-analysis of asthma GWASs. The TAGC meta-analysis of asthma GWAS also showed that the 17q12-21 locus centered on *ORMDL3*/*GSDMB* was specific to early-onset asthma, while that SNPs at the *PGAP3*/*ERBB2* loci were not.[@B14] They also suggested that the asthma-associated signals near the *PGAP3/ERBB2* and *ORMDL3/GSDMB* blocks may affect asthma risk through the expression of different genes in different tissues.[@B14][@B15] Of note, the effects of genotype at this locus on asthma risk and protection have been reported to be modified by early-life exposures including environmental tobacco smoking[@B17] and rhinovirus (RV)-associated wheezing in the first 3 years of life.[@B18] Despite its strong and consistent association with asthma, there has been little evidence of association at this locus in African ancestry populations,[@B14][@B19] possibly owing to the breakdown of LD on African-derived chromosome.[@B15] Taken together, SNPs in this locus are robustly associated with childhood-onset asthma in European, Asian and Latino individuals. Stein *et al*.[@B15] recently reviewed studies of the 17q12-21 locus that showed the asthma-associated 17q12-21 SNPs are eQTLs for the *GSDMA*, *ORMDL3, GSDMB* and *PGAP3* in immune cells and/or lung cells. However, the role of 17q12-21 genes in asthma pathogenesis is still unknown. An overview of functional studies of genes at the 17q12-21 locus was reviewed recently by Das *et al*.[@B20]

Among the approximately half of the published GWAS of asthma that did not identify any genome-wide significant associations in their discovery stage, most had sample sizes \< 2,000 subjects ([Table 1](#T1){ref-type="table"}) suggesting that larger sample sizes (≥10,000) are needed to identify asthma associated loci. For example, the TAGC meta-analysis showed that pooling data from ethnically diverse populations including 23,948 asthma cases and 118,538 controls,[@B14] and a 23andMe GWAS in 28,399 European ancestry cases and 128,843 controls[@B21] each detected new asthma loci. Although very large studies increase clinical heterogeneity, many true asthma loci can be detected in very large samples.

GWAS OF ASTHMA SUB-PHENOTYPES AND INTERACTIONS
==============================================

GWASs of asthma sub-phenotypes reduce heterogeneity and can lead to the identification of new asthma risk loci, even in smaller samples, due to increased power in studies of extreme or more homogeneous phenotypes. These studies may unveil genetic factors that are 'masked' in very large GWAS of more heterogeneous cases. For example, this is best illustrated by a GWAS of early childhood asthma with acute exacerbations leading to hospitalization and emergency department visit by Bønnelykke *et al*.[@B22] The *CDHR3* at 7q22.3 was identified in this study as a new susceptibility gene; this locus was later shown to be genome-wide significant in the 23andMe GWAS in European ancestry individuals,[@B21] but not in the TAGC meta-analysis of ethnically diverse individuals.[@B14] Importantly though, subsequent studies showed that *CDHR3* functions as a receptor for Rhinovirus C (RV-C),[@B23] and that the *CDHR3* asthma risk allele was associated specifically with RV-C-related respiratory illnesses in the first 3 years of life.[@B24] This "exacerbation GWAS" also confirmed previously reported asthma loci at genome-wide significance --- *GSDMB* at 17q21, *IL33* at 9p24*, RAD50* at 5q31 and *IL1RL1* at 2q12 loci, but with larger effect sizes despite the smaller sample size ([Table 2](#T2){ref-type="table"}), demonstrating that careful phenotyping and reduced clinical heterogeneity can reveal both novel asthma loci and larger effects of associated loci in smaller sample sizes than typically required for GWAS.

Another GWAS of exacerbations in 2 pediatric cohorts reported a novel asthma locus at the 10q21.3 (*CTNNA3*) that was genome-wide significant.[@B25] A meta-analysis of GWASs that included both physician-diagnosed asthma and hay fever compared to controls with neither asthma nor hay fever revealed 2 novel susceptible loci: *ZBTB10* at 8q21.13 and *CLEC16A* at 16p13.13.[@B26] A GWAS of asthma with reduced exposure to tobacco smoke identified a locus that included the gene, *HAS2* at 8q24.13, as a susceptibility locus,[@B27] and another GWAS of active adult-onset nonallergic asthma added novel loci to asthma susceptible genes, *CD200* at 3q13.2 and *GRIK2* at 6q16.3, compared to inactive and mild nonallergic asthma.[@B28] A GWAS that investigated the age of onset of childhood asthma, revealed loci on 3p26 and 11q24 that were associated with early-onset asthma and potentially to more severe disease.[@B29] These GWASs of asthma defined by the presence or absence of other conditions identify novel loci, but most still require replication and functional characterizations.

Another approach to disentangle the complexity of asthma phenotypes and account for potential heterogeneity of risk factors have been genome-wide interaction studies (GWISs). A GWIS of genotype-by-sex interactions revealed a male-specific asthma risk locus, which includes *IRF1* at 5q31.1, in European ancestry individuals, and a female-specific asthma risk locus, which included *RAP1GAP1* at 1p36.12, in Latino individuals.[@B30] The SNPs at these 2 loci showed only nominally significant associations with asthma in an independent GWAS, but emerged as sex-specific asthma risk loci when the effects of both genotype and sex as an interaction were taken into account. Another GWIS of farm-related exposures on asthma and atopy risk did not show any significant associations with either novel or previously reported asthma loci, likely due to low statistical power.[@B31] Although this is a promising approach to identify loci that may confer risk only in the presence of specific exposures (*i.e*., gene-environment interactions), it is challenging to conduct these studies in the very large samples because exposures histories are rarely available in those samples.[@B8]

Finally, gene discovery in smaller samples may be possible using validated phenotyping algorithms that mine electronic medical records (EMRs). This approach has recently been developed as a tool for genomic research by the Electronic Medical Records and Genomics (eMERGE) network.[@B32][@B33] A GWAS of asthma in 5,309 cases and 16,335 controls recruited from eMERGE network identified novel loci of 6p21.31 (*GRM4*) and 9p21.2 (*EQTN*),[@B34] although these associations need further replication and functional characterization. Within EMRs, longitudinal phenotype data and immense amounts of secondary phenotype data, such as laboratory findings and drug responses, can be collected. These data can be analyzed along with genetic data to determine whether loci are specific to asthma or shared with other allergic phenotypes, or how these relationships change over time. Rapid adoption of EMRs and EMR data standardization across hospitals will make available extensive phenotype data on many diseases and, combined with patient genotyping, expedite the identification of shared and unique genetic signatures for asthma endotypes as well as all common diseases.

GWAS OF ASTHMA-RELATED TRAITS
=============================

GWASs have been reported for asthma-related traits such as BDR, AHR, blood eosinophils, total serum IgE levels and allergic sensitization. The general assumptions of these studies are that it may be easier to find genes influencing components of asthma because they are less heterogeneous than asthma *per se*, and those same genes may also contribute to asthma risk and potentially provide more direct pharmacologic targets.

A GWAS of BDR --- defined as the percentage change in FEV1 after administration of a short-acting β~2~-adrenergic receptor agonist --- identified rare variants (frequency, \<5%) near the solute carrier (SLC) genes with genome-wide significance in 1,782 Latino asthmatic children.[@B35] Another GWAS of BDR revealed genome-wide significant variants near the *ASB3* gene at 2p16 in a combined analysis of 1,164 multi-ethnic individuals with asthma.[@B36] A GWAS of AHR severity --- defined as the natural log of the dosage of methacholine causing a 20% drop in FEV1 --- in 994 non-Hispanic white asthmatic subjects did not identify any genome-wide significant genes,[@B37] while another GWAS of AHR severity in 650 European adult asthmatics revealed SNPs at the *PDE4D* gene at 5q11 at genome-wide significance,[@B38] which is a previously reported asthma gene.[@B39] Overall however, the BDR and AHR genes identified in GWAS with relatively small sample sizes lack replication. In contrast, a large GWAS of blood eosinophils,[@B40] pleotropic multifunctional leukocytes that are involved in the pathogenesis of inflammatory diseases including asthma, in 21,510 European subjects (comprised of a discovery, n = 9,392, and replication, n = 12,118, sample) reported SNPs near the *IL1RL1* at 2q12, *IKZF2* at 2q34, *GATA2* at 3q21.3, *IL5* at 5q31.1 and *SH2B3* at 12q24.12 genes with genome-wide significance. Among them, a variant at *IL1RL1* was also associated with asthma in 10 different populations included in this study. *IL1RL1* has been reported as an asthma gene through multiple GWAS of asthma ([Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). This finding requires further functional characterization if its relationship to eosinophils, asthma, and especially eosinophilic asthma, and its potential as a therapeutic target.

The first GWAS of total serum IgE levels, which is a strongly heritable trait,[@B41][@B42] did not show any genome-wide significant associations in the discovery population of 1,530 individuals of European ancestry. However, by combining the GWAS results with 4 independent replication cohorts, the investigators showed that functional variants near the gene encoding *FCER1A* at 1q23.2 and at the *RAD50-IL13* locus at 5q31 were associated with total serum IgE levels at genome-wide significant thresholds in a combined analysis in of 11,299 individuals of European ancestry.[@B43] The Multidisciplinary Study to Identify the Genetic and Environmental Causes of Asthma in the European Community (GABRIEL) consortium identified SNPs near *HLA-DRB1* at 6p21 as an IgE-associated locus that was independent of associations of this locus with asthma, and confirmed the previously reported associations between total serum IgE levels and SNPs near the *FCER1A*, *RAD50-IL13* and *STAT6* loci, at genome-wide significant level.[@B16] Three more GWAS of total serum IgE levels revealed loci near the HLA region reaching genome-wide significance;[@B44][@B45][@B46] the EVE consortium confirmed that these associations were shared among diverse ethnic groups.[@B47] A GWAS of total serum IgE levels in 3,334 Latinos and a following admixture mapping in 454 Latinos, 1,564 European Americans and 3,187 African Americans revealed a locus near the *ZNF365* gene at 10q21, but this finding still lacks replication.[@B45] Furthermore, a meta-analysis of GWASs of allergic sensitization in 15,845 individuals of European ancestry and replication in 16,034 individuals of European ancestry identified 10 genome-wide significant loci in or near *TLR6* at 4p14, *C11orf30* at 11q13, *STAT6* at 12q13, *SLC25A46* at 5q22, *HLA-DQB1* at 6p21, *IL1RL1* at 2q12, *LPP* at 3q28, *MYC* at 8q24, *IL2* at 4q27 and *HLA-B* at 6p21.[@B48] A recent GWAS of allergic disease in 360,838 individuals considered individuals with asthma, hay fever and/or eczema.[@B49] They identified 136 genome-wide significant risk variants at 99 independent loci, most of which had similar effects on the individual diseases, reflecting etiologic pathways that are common to all 3 diseases. However, this did not explicitly test for independent effects of the associated loci among individuals with only one of the three diseases. The shared loci were predicted to influence the function of immune cells and their target genes suggested opportunities for genomics-guided drug repositioning.

FUNCTIONAL STUDIES OF ASSOCIATED SNPs FROM EXISTING GWAS
========================================================

A limitation of GWAS is that it identifies SNPs but does not provide information on the genes that the associated SNPs influence or on the causal SNP(s) among all SNPs in strong LD. As a result, nearly all GWASs report the nearest gene(s) as potential asthma candidate genes. However, not all SNPs impact the function or expression of the nearest gene, even when the SNP is within the gene itself. For example, among disease-associated variants that are eQTLs, the target gene will differ from the nearest gene 34% of the time.[@B50] On the other hand, SNPs that are eQTLs are more likely to be among significant GWAS SNPs compared to SNPs that are not eQTLs,[@B51] and combining eQTL mapping with GWAS can link GWAS-associated variants with the gene(s) they regulate, particularly if studies are performed in disease-relevant tissues.[@B15] For example, Li *et al*.[@B52] performed *cis*-eQTL studies in human bronchial epithelial cells (BECs) and cells from bronchial alveolar lavage (BAL) using SNPs near 34 putative asthma genes at 23 loci from previous GWASs. SNPs at 9 of the 23 loci were associated with the expression of nine genes in either BEC or BAL: *IL1RL1* (but not *IL18R1*) at 2q12, *TSLP* (but not *WDR36*) at 5q22, *HLA-DQB1* at 6p21*, CDHR3* at 7q22*, ZBTB10* at 8q21, *IL33* at 9p24*,* *C11orf30* (but not *LRRC32*) at 11q13*, DEXI* (but not *CLEC16A*) at 16p13*,* and *GSDMB* (but not *ORMDL3*) at 17q21. There are likely to be additional *cis*-eQTLs at asthma-associated SNPs at some of these loci in other tissues or by considering more SNPs or genes at each locus.

Ferreira *et al*.[@B53] used a gene-based association test that integrated published asthma GWAS and eQTL mapping studies to identify SNPs that are eQTLs and the genes they are associating with. They used 16 published eQTL studies in 12 cell types or tissues potentially relevant to asthma: whole blood, lymphoblastoid cell lines, peripheral blood mononuclear cells, monocytes, B cells, T cells, neutrophils, spleen, lung, small airways, fibroblasts, skin. They suggested that asthma risk was associated with the expression of genes related to nucleotide synthesis (*B4GALT3* at 1q23.3 and *USMG5* at 10q24.33) and nucleotide-dependent cell activation (*P2RY13* and *P2RY14* at 3q25.1), and referred to these genes as putative novel asthma risk genes. They applied this method to their recent large GWAS of allergic disease,[@B49] and identified additional significant and reproducible gene-based associations with 19 genes at 11 loci that were missed by single-variant analyses reported in the previous GWASs.[@B54] Among these were nine genes with known functions relevant to allergic disease: *FOSL2* at 2p23, *VPRBP* at 3p21, *IPCEF1* at 6q25, *PRR5L* at 11p13, *NCF4* at 22q12, and *APOBR*, *IL27*, *ATXN2L* and *LAT* at 16p11. These putative novel associations still need further replication. Luo *et al*.[@B55] combined asthma GWAS results and publicly available eQTL data from human epithelial cells from small and large airways. They demonstrated that asthma GWAS hits were enriched as airway epithelial eQTLs and genes regulated by asthma GWAS loci in epithelium were enriched in immune response pathways. Li *et al*.,[@B52] Ferreria *et al*.,[@B53] and Luo *et al*.[@B55] linked asthma-associated SNPs to genes they regulate, potentially elucidating molecular mechanisms for their associations with asthma.[@B53][@B55] A great boon to this type of approaches is the Genotype-Tissue Expression (GTEx) consortium, which has made available eQTL data for 44 human tissues that can be used to identify genes and pathways affected by human disease-associated variation.[@B56]

GWAS OF ASTHMA OR ASTHMA-RELATED TRAITS IN THE KOREAN POPULATION
================================================================

In 2008, the first GWAS of an asthma phenotype in 347 Korean subjects (84 cases and 263 controls) was published for toluene diisocyanate (TDI)-induced asthma, an occupation-associated form of asthma.[@B57] Since then, GWASs of asthma in Korea focused on 80,[@B58] 100,[@B59] 117[@B60] and 179[@B61] subjects with AERD, which is characterized by the development of bronchoconstriction in asthmatic patients after ingestion of non-steroidal anti-inflammatory drugs including aspirin. However, no genome-wide significant loci were reported in these GWASs, likely due to small sample sizes.

A GWAS of total serum IgE levels was reported in 877 Korean asthmatic patients without any genome-wide significant hits,[@B62] but a GWAS of asthma in the Korean population has not yet been published. Performing GWASs of asthma in Korean children and adults is called for in the near future in order to identify the major genetic susceptibilities that maybe unique to this population.

ISSUES AND CHALLENGES IN GWAS OF ASTHMA
=======================================

Despite their power for identifying asthma risk loci, there are many limitations of GWASs. In particular, GWASs identify mostly common variants which tend to have small effect sizes. As a result, GWAS-discovered variants are largely common (MAF \> 10%) and account for a small proportion of both the population prevalence and the genetic component of asthma (*i.e.,* the heritability).[@B63][@B64][@B65] These results in limited predictive power of these variants.[@B66][@B67] Although rare and low-frequency variants have potentially larger phenotypic effects, they have not explained a significant fraction of the 'missingness' of asthma heritability thus far.[@B68] Recently, in a whole-genome sequencing study, Smith *et al*.[@B69] found a rare loss of function mutation in *IL33* that was associated with both lower blood eosinophils in 103,104 European subjects and reduced risk of asthma in 6,465 European asthmatic subjects and 302,977 controls. This study suggests that rare variants with large effect sizes are segregating in the population. While it is unlikely that such rare variants will account for significant proportions of the population risk for asthma, they can identify new pharmacologic targets and therefore serve a very important function.

Another limitation of GWAS is the statistical approach that tests for association with each of potentially tens of millions of SNPs. As a result, adjustments for multiple testing, typically using a Bonferroni corrected *P* value of \<5 × 10^−8^ to control the false positive rate, require very large sample sizes (potentially \>100,000) to identify loci with modest effect sizes. This stringent significance threshold will miss many true associations, particularly with SNPs involved in gene-gene and gene-environment interactions or those that are associated with specific asthma endotypes or sub-phenotypes. These variants have been referred to as 'mid-hanging fruit' in GWAS,[@B7] and differentiating true from false associations among variants with small *P* values (*e.g.*, \<10^−4^) that do not meet genome-wide significance thresholds in GWASs remains a major challenge.

Another limitation has been that most GWAS and large meta-analyses of asthma and related traits are in subjects of European ancestry. Thus, most inferences about the genetic architecture of asthma is based on observations in this one continental population, whereas much less is known about Asian, African and admixed populations. Because populations vary with respect to allele frequencies, patterns of LD, and effect sizes of variants that underlie disease risk,[@B70][@B71][@B72] inferences based on Europeans may have limited utility in other groups. For example, next-generation sequencing studies revealed differences in allele frequencies and haplotype structures at the 17q12-21 asthma-locus between Chinese and other ethnic groups.[@B73] However, half of the 24 asthma GWAS are only in Europeans ([Table 1](#T1){ref-type="table"}), and those studies are in general the largest GWAS to date. Moreover, until recently, commercial genotyping arrays were based on European allele frequencies and LD patterns. As a result, GWAS in non-European populations likely missed variants specific to those populations. This also impacts the selection of tag SNPs in replication studies in non-European populations. These issues have recently been addressed by the development of ethnic-specific and pan-ethnic genotyping arrays and publicly available genome sequences that allow for ethnic-specific imputation of genome-wide SNPs.[@B74] For the first time, GWAS in Asian, Latino and African populations can be performed with excellent SNP coverage. It is crucial to study populations of diverse ethnic backgrounds for identifying shared and unique genetic predictors of asthma and for capturing more global patterns of genetic risk and gene-environment interaction effects on asthma risk.

CONCLUSIONS
===========

Asthma pathogenesis is complex, resulting from heterogeneous genetic and environmental factors that jointly give rise to extensive phenotypic heterogeneity among asthmatics. Age at time of exposure to environmental risk factors and the persistence of these exposures during the lifespan may be critical modifiers of genotype-specific risk. These considerations are rarely, if ever, accounted for in GWAS. Nonetheless, the identification of susceptibility variants has already provided mechanistic insights into asthma pathogenesis, suggesting that asthma risk variants play a role in the regulation of immune cell functions.[@B14] GWAS findings, considered together with deep learning approaches that can incorporate longitudinal EMR data,[@B75] have the potential to more fully elucidate the genetic architecture of asthma. Such insights can be translated into advances in clinical care through identifying therapeutic targets and preventive approaches and ultimately personalized medicine.[@B67]
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